Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedFeb 10, 2026
DataAggregated Company Financials
Companies21
  • 7D-14.7%
  • 3M-3.3%
  • 1Y-44.0%
  • YTD-6.4%

Over the last 7 days, the Healthcare industry has dropped 18%, driven by Novo Nordisk declining 17%. The industry has fallen 46% in the last year. Earnings are forecast to grow by 3.4% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 10 Feb 2026DKK 1.8tDKK 448.0bDKK 134.8b16.3x13.6x4.1x
Thu, 08 Jan 2026DKK 2.1tDKK 453.9bDKK 136.9b17.6x15.6x4.7x
Sat, 06 Dec 2025DKK 1.9tDKK 454.0bDKK 137.0b17.3x13.8x4.1x
Mon, 03 Nov 2025DKK 1.9tDKK 448.0bDKK 141.9b17.2x13.4x4.3x
Wed, 01 Oct 2025DKK 2.0tDKK 447.3bDKK 141.7b17.6x14.2x4.5x
Fri, 29 Aug 2025DKK 2.1tDKK 447.4bDKK 141.7b24.5x14.6x4.6x
Sun, 27 Jul 2025DKK 2.5tDKK 423.1bDKK 124.5b30.1x19.9x5.9x
Tue, 24 Jun 2025DKK 2.5tDKK 423.4bDKK 124.6b30.4x19.7x5.8x
Thu, 22 May 2025DKK 2.5tDKK 424.3bDKK 125.1b24.1x19.9x5.9x
Sat, 19 Apr 2025DKK 2.3tDKK 409.2bDKK 121.3b21.8x19.1x5.7x
Mon, 17 Mar 2025DKK 2.8tDKK 409.5bDKK 121.3b24.9x23.5x7x
Wed, 12 Feb 2025DKK 3.2tDKK 408.3bDKK 118.3b28.1x27.1x7.8x
Fri, 10 Jan 2025DKK 3.4tDKK 387.5bDKK 111.3b30.3x30.1x8.6x
Sun, 08 Dec 2024DKK 4.0tDKK 387.3bDKK 111.3b31.3x36.3x10.4x
Tue, 05 Nov 2024DKK 3.9tDKK 372.2bDKK 107.2b33.2x36.5x10.5x
Thu, 03 Oct 2024DKK 4.1tDKK 372.0bDKK 107.1b36.3x38.4x11.1x
Sat, 31 Aug 2024DKK 4.8tDKK 371.8bDKK 107.1b35.5x44.7x12.9x
Mon, 29 Jul 2024DKK 4.5tDKK 355.4bDKK 106.3b35.9x42.1x12.6x
Wed, 26 Jun 2024DKK 5.1tDKK 355.3bDKK 106.2b34.3x48.3x14.5x
Fri, 24 May 2024DKK 4.7tDKK 355.3bDKK 106.2b37.6x44.6x13.3x
Sun, 21 Apr 2024DKK 4.4tDKK 341.3bDKK 99.6b33.3x44.5x13x
Tue, 19 Mar 2024DKK 4.7tDKK 341.2bDKK 99.6b39.2x46.9x13.7x
Thu, 15 Feb 2024DKK 4.3tDKK 340.5bDKK 98.6b34.9x44x12.7x
Sat, 13 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b33.5x42x11.8x
Mon, 11 Dec 2023DKK 3.5tDKK 320.6bDKK 90.0b33.8x38.9x10.9x
Wed, 08 Nov 2023DKK 3.6tDKK 318.7bDKK 90.3b29.3x40.2x11.4x
Fri, 06 Oct 2023DKK 3.3tDKK 305.5bDKK 82.2b32.7x40.7x11x
Sun, 03 Sep 2023DKK 3.5tDKK 305.4bDKK 82.2b36.7x42x11.3x
Tue, 01 Aug 2023DKK 3.0tDKK 287.2bDKK 75.5b37.6x39.7x10.4x
Thu, 29 Jun 2023DKK 2.9tDKK 287.1bDKK 75.5b39.1x38.3x10.1x
Sat, 27 May 2023DKK 3.1tDKK 287.2bDKK 75.5b41.8x41.4x10.9x
Mon, 24 Apr 2023DKK 3.2tDKK 272.6bDKK 68.5b44x46.7x11.7x
Wed, 22 Mar 2023DKK 2.8tDKK 292.5bDKK 69.2b37.9x40.5x9.6x
Fri, 17 Feb 2023DKK 2.7tDKK 289.4bDKK 68.9b39.4x39.9x9.5x
Price to Earnings Ratio

39.9x


Total Market Cap: DKK 2.7tTotal Earnings: DKK 68.9bTotal Revenue: DKK 289.4bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 33.1x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 13.1x which is lower than its 3-year average PE of 33.2x.
  • The 3-year average PS ratio of 9.4x is higher than the industry's current PS ratio of 3.9x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 25% per year over the last three years.
  • Revenues for these companies have grown 16% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market-6.39%
Healthcare-14.66%
Healthcare Services-2.53%
Healthtech-4.49%
Biotech-6.03%
Medical Equipment-10.07%
Pharma-15.97%
Life Sciences-23.70%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 334x.
    • Analysts are expecting annual earnings growth of 85.3%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 96% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 23% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ALK B ALK-AbellóDKK 216.001.9%
+DKK 884.8m		35.3%PE43.4x
AMBU B AmbuDKK 86.351.9%
+DKK 437.9m		-35.5%PE42.1x
PEG Pharma Equity GroupDKK 0.115.4%
+DKK 6.8m		-29.8%PB3.3x
BIOPOR BioPortoDKK 0.980.1%
+DKK 495.1k		-35.9%PS13.3x
BRAINP Brain+DKK 0.002420.0%
+DKK 453.2k		-96.0%PS0.5x

Latest News

AMBU B
DKK 86.35
Ambu
7D
1.9%
1Y
-35.5%

AMBU B: Higher Risk Premium And Margin Pressure Will Reshape Share Outlook

The analyst price target for Ambu has been reduced from DKK 94.54 to DKK 78.00. This change reflects analysts’ updated assumptions on discount rate, revenue growth, profit margin and future P/E, as highlighted by recent Street research including a DKK 12 target cut.
DEMANT
DKK 183.40
Demant
7D
-17.5%
1Y
-31.5%

DEMANT: Future Margin Resilience And Cautious Ratings May Support Upside Potential

Analysts have trimmed their price targets on Demant by about DKK 28, reflecting updated assumptions for slightly higher revenue growth, a lower future P/E multiple, and a modestly softer profit margin, in line with recent cautious moves from several major banks and a Sector Perform stance from RBC Capital. Analyst Commentary Recent research updates on Demant point to a broadly cautious tone, with several banks adjusting price targets and at least one downgrade in rating.
HLUN B
DKK 38.50
H. Lundbeck
7D
-9.6%
1Y
-10.2%

HLUN B: Weaker Long Term Revenue And Margin Outlook Will Pressure Shares

Analysts have reduced their price target on H. Lundbeck from €39.00 to €34.00, citing updated assumptions for revenue growth, profit margins, and a slightly higher discount rate, while keeping the forward P/E outlook broadly similar.
NOVO B
DKK 311.00
Novo Nordisk
7D
-16.6%
1Y
-49.5%

Novo Nordisk (CPH:NOVO B) Is Paying Out A Larger Dividend Than Last Year

Feb 08
Novo Nordisk (CPH:NOVO B) Is Paying Out A Larger Dividend Than Last Year
CHEMM
DKK 407.00
ChemoMetec
7D
-33.6%
1Y
-28.8%

ChemoMetec A/S' (CPH:CHEMM) 40% Cheaper Price Remains In Tune With Earnings

Feb 08
ChemoMetec A/S' (CPH:CHEMM) 40% Cheaper Price Remains In Tune With Earnings
COLO B
DKK 481.00
Coloplast
7D
-10.4%
1Y
-38.6%
BIOPOR
DKK 0.98
BioPorto
7D
0.1%
1Y
-35.9%
ZEAL
DKK 415.90
Zealand Pharma
7D
-2.7%
1Y
-41.9%
PEG
DKK 0.11
Pharma Equity Group
7D
5.4%
1Y
-29.8%
GMAB
DKK 1,931.50
Genmab
7D
-7.6%
1Y
41.2%

GMAB: Phase 3 Data, AI Adoption And 2026 Readout Will Shape Outlook

Genmab’s analyst fair value estimate has moved modestly higher to DKK 2,188.94. Analysts point to updated assumptions around slightly lower discount rates, adjusted revenue growth and profit margin expectations, and a recalibrated future P/E multiple as the key drivers behind the refreshed price targets.
ALK B
DKK 216.00
ALK-Abelló
7D
1.9%
1Y
35.3%
BRAINP
DKK 0.0024
Brain+
7D
20.0%
1Y
-96.0%
GUBRA
DKK 413.20
Gubra
7D
-9.2%
1Y
-35.8%
MONSO
DKK 0.15
Monsenso
7D
1.3%
1Y
-43.0%